Search

everythinglearnresearchcommunity

for

Search:↓

KX-826 hair loss treatment completed trials with mild side effects. GT20029 may be ultimate cure, destroying androgen receptors causing baldness.

A 29-year-old male shares his hair loss treatment progress using dutasteride, minoxidil, dermastamping, and ketoconazole shampoo, while discontinuing RU58841 due to side effects. He is hopeful for hair recovery to consider a hair transplant and discusses potential side effects and experiences with other users.

The conversation discusses a hair loss treatment regimen involving dutasteride, pyrilutamide, oral minoxidil, and microneedling, with the aim of suppressing DHT and stimulating hair growth. Users debate the effectiveness and potential side effects of these treatments, noting that individual results may vary and that no treatment is foolproof.

Spironolactone, finasteride, and dutasteride are discussed for hair maintenance, with concerns about testosterone and side effects like gynecomastia. Spironolactone is noted for use in both bodybuilding and hormone therapy, with low doses considered for minimizing side effects.

Promising hair loss treatments in clinical trials include Pyrilutamide, GT20029, CB-03-01, and PP405, with potential market releases between 2027 and 2029. Hair cloning remains experimental and expensive, while existing treatments like finasteride, minoxidil, and microneedling continue to be used.

A 24-year-old male using topical finasteride for hair loss is experiencing thinning despite treatment and has high estrogen levels. He is seeking advice on whether high estrogen could be causing hair loss and how others with high estrogen levels have addressed it.

A user plans to undergo a temporary MtF transformation to regrow hair, using estrogen, RU58841, and Dutasteride, then revert with testosterone. Many users criticize the plan, suggesting alternatives like hair transplants, and emphasize that estrogen is not a reliable solution for hair regrowth.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

A 28-year-old male experiencing diffuse thinning and miniaturization around the ears and back has tried finasteride, dutasteride, and both topical and oral minoxidil without success. He is seeking advice on identifying the type of hair loss and next steps since current treatments are ineffective.

Low estrogen levels may reduce the risk of side effects from finasteride, such as gynecomastia. Some users plan to start with microneedling and minoxidil before trying finasteride, while others have experienced temporary side effects from topical finasteride but continued use without persistent issues.

Topical spironolactone is considered safe for males but is not very effective for hair loss. Some users suggest trying it since it's already purchased, while others recommend alternatives like clascoterone.

A 35-year-old has seen no hair regrowth after 9 months using treatments including finasteride, pyrilutamide, microneedling, ketoconazole shampoo, and topical dutasteride, but experienced side effects with RU58841. Commenters suggest starting minoxidil for better results and question why it wasn't included from the beginning.

The conversation is about a user making a homemade topical dutasteride solution to use alongside testosterone replacement therapy (TRT) and oral dutasteride. The user aims to reduce DHT locally at the testosterone injection site and on the scalp.

A young man faces severe hair loss in his early 20s, using treatments like dutasteride and minoxidil with little success, impacting his self-esteem and relationships. He considers hair systems and therapy as potential solutions.

After 4 months of using topical finasteride and minoxidil, blood tests showed increased E2, Test, and Prolactine levels. The user is concerned about potential side effects like gyno and is seeking advice on managing these values.

User TopBack56 and friends tried pyrilutamide (KX-826) for hair loss without experiencing negative side effects. They observed fine vellus hairs but no thick hair growth yet, and plan to add GT20029 to their regime after safety trials.

The user experienced excessive scalp oiliness and high testosterone levels after switching from finasteride to dutasteride. They plan to manage their condition with finasteride and are considering spironolactone to reduce testosterone and restore dry skin.

The user is experiencing intense hair shedding all over the scalp after applying pyrilutamide to the hairline and taking oral castor oil. They are also using topical finasteride and latanoprost, but are unsure which treatment is causing the shedding.

A dermatologist advised a patient to stop taking finasteride (fin) after turning 40 due to potential risk of aggressive prostate cancer. The patient and others in the conversation debated this advice, discussing the relationship between finasteride, prostate cancer, and hair loss, and considering alternatives like topical finasteride.

The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

A 20-year-old saw significant hair regrowth after 9 months of using DHT blockers (finasteride and dutasteride) and 6 months of hormone replacement therapy (HRT) with estradiol. The regrowth is attributed to low testosterone and high estradiol levels, without using Minoxidil.

RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.

The conversation is about choosing an anti-androgen for hair loss treatment, with options being alfatradiol and pyrilutamide. Alfatradiol is considered a better choice due to its established use, while pyrilutamide is more experimental.

The user has seen no regrowth after 1 year and 2 months on finasteride, despite increasing the dose, and is inquiring about the potential of future treatments like verteporfin and gt20029 for hair regrowth.

Androgenic alopecia (AGA) might have evolved to reduce prostate cancer risk by increasing UV exposure to the scalp, but this theory is debated. Treatments like minoxidil and finasteride are used for AGA, though the exact causes and evolutionary reasons for hair loss are unclear.

A 19-year-old is using oral dutasteride, topical minoxidil, and dermastamping to address hair loss and enhance facial hair growth, experiencing minimal side effects and increased body hair. They report positive results in hairline thickness and temple closure.

The user is concerned about high prolactin levels and low testosterone levels after stopping finasteride for three weeks. They are considering resuming finasteride but are worried it might further increase prolactin levels.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

The user is concerned about hair loss despite taking finasteride and has a hair transplant scheduled. They experience scalp itching and burning, which hasn't been relieved by various treatments, and another user suggests using ghk-cu & ahk-cu serum and Koshine kx-826/pyrilutamide for relief.

A 19-year-old male is experiencing accelerated hair recession after two months on oral Dutasteride, despite no noticeable shedding, while also using topical Minoxidil and Finasteride. He is unsure if the treatment is effective and is unable to access RU58841.